Navigation Links
CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Date:4/1/2008

Data Presented at annual American College of Cardiology (ACC) Scientific Sessions Demonstrates Further Potential of Company's Platform ECM(TM)

Technology

CHICAGO and ATLANTA, April 1, 2008 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial technologies that harness the body's innate ability to repair damaged cardiovascular tissue, presented data on its ECM Technology(TM) this week at the annual American College of Cardiology (ACC) Scientific Sessions in Chicago. Data demonstrated that ECM Technology(TM), in the form of an injectable emulsion, enhanced angiogenesis, increased recruitment of C-kit positive progenitor stem cells, and improved cardiac function in a rat model.

The study, conducted at Emory University, used rats that were subjected to 45 minutes of coronary occlusion, followed by an injection of either the ECM Technology emulsion or a saline control into the affected myocardium and examined at three, seven, 21 and 42 days.

"The animals that received injections of the ECM Technology in an emulsified version demonstrated a significant reversal of cardiac damage and sustained improvements in ejection fraction and overall cardiac function," said Robert Matheny, M.D., Chief Scientific Officer, CorMatrix Cardiovascular, who co-authored the study. "We are very encouraged by this data and intend to continue to analyze the unique remodeling characteristics of the ECM material."

Study Results

At 42 days post-injection, the population of C-kit positive progenitor stem cells in the ECM emulsion area and adjacent borders increased a statistically significant amount relative to the control group, which received saline injections (32 +/- 0.6 vs. 15 +/- 3.0 per 1000 nuclei). Enhanced angiogenesis in the ECM Technology emulsion area was also statistically significant. In addition, echocardiography showed statistical improvements in end-systolic volume (0.3 +/- 0.1 vs. 0.6 +/- 0.3 ml), fractional shortening (33 +/- 5 vs. 24 +/- 6%) and ejection fraction (67 +/- 6 vs. 53 +/- 10%). The wall thickness of the infarcted middle anterior septum in the injected group was also statistically greater than that in the control (0.19 +/- 0.02 vs. 0.15 +/- 0.02cm).

"This data demonstrates the unique potential of the extracellular matrix material in cardiac applications," said Beecher Lewis, President and COO of CorMatrix. "We are very excited about the results of this study and will continue to evaluate the broad potential utility of our patented ECM Technology."

Currently, the Company's platform ECM Technology is U.S. Food and Drug Administration (FDA) cleared and in use for pericardial closure. The Company is researching a variety of cardiovascular applications using the patented ECM Technology.

About Extracellular Matrix Biomaterial

The unique properties of extracellular matrix biomaterials were discovered at Purdue University. The decellularized matrix material serves as a scaffold to allow adjacent tissues to deliver cells and nutrients to the matrix, which then differentiate into tissue-specific cells. The ECM material is gradually replaced, as the patient's own body reinforces and rebuilds the weakened site. During the repair, the matrix is rapidly degraded and resorbed, leaving remodeled functional tissue where scar tissue or injured tissue would normally be expected.

The use of extracellular matrix materials in non-cardiovascular applications has established a significant foothold in soft tissue repair, wound management and orthopedic applications. The safety of extracellular matrices has been well established in a number of different clinical applications. The extracellular matrix has been studied extensively, with more than 500 published papers. Since 1999, an estimated 500,000 patients worldwide have received an extracellular matrix implant.

About CorMatrix ECM Technology(TM)

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring extracellular matrix products for cardiovascular applications. CorMatrix is currently conducting a number of preclinical studies utilizing the ECM Technology for a variety of cardiovascular applications. The company has U.S. and European approval to market the CorMatrix ECM Technology(TM) as an implant for pericardial closure.

About CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative biomaterial devices that harness the body's innate ability to repair damaged cardiovascular structures. For more information visit http://www.cormatrix.com.


'/>"/>
SOURCE CorMatrix Cardiovascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test para el mercado ... Continue Reading ... New: INSTI Self Test! ... , bioLytical Laboratories (la "Compañía"), un líder mundial ... lanzamiento de su INSTI HIV Self Test  a África con una versión de ...
(Date:12/2/2016)... According to the latest market report published by ... Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type Segment Anticipated ... the global automated endoscope reprocessors market was valued at US$ 740.6 Mn ... of 7.2% during an eight-year forecast period 2016-2024, to reach ... ...
(Date:12/2/2016)... , Dec. 2, 2016 In the ... sources apart from those derived from C. sativa, the ... Universita` di Napoli Federico II , the Universita` ... the first comprehensive, critical, integrated and unified inventory of ... article focuses on the remarkable chemical and structural ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to host ... other developmental disabilities. The group, which is being launched with the help of Robbie ... share stories and advice, seek help, and continue their education on how to best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... Cleveland, OH (PRWEB) , ... December 02, 2016 ... ... provider of veterinarian diagnostic imaging systems and the first company to ... Robot With a Heart at their tradeshow booth # 941 for the American ...
(Date:12/2/2016)... ... 02, 2016 , ... Clarify Health Solutions, Inc., the leading ... in an initial round of funding. The round was led by experienced investors ... receive far better care through the application of the best technologies from other ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... to announce that we have been designated as a Cigna Infertility Center of ... exceed rigorous performance standards. , “It’s an honor to be designated a ...
Breaking Medicine News(10 mins):